Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers

Patients with chronic hepatitis B (CHB) who were administered tenofovir disoproxil fumarate (TDF)-based combination therapy after receiving multiple drugs are frequently switched to TDF monotherapy in South Korea. We evaluated the efficacy and safety of switching to TDF monotherapy from TDF-based co...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2022-08, Vol.66 (8), p.e0027522-e0027522
Main Authors: Kim, Jung Hun, Kim, Jeong Han, Choe, Won Hyeok, Kwon, So Young, Yoo, Byung-Chul, Yoon, Eileen L, Kang, Seong Hee
Format: Article
Language:English
Subjects:
Antimicrobial Chemotherapy
Antiviral Agents
DNA, Viral
Drug Resistance, Viral
Drug Therapy, Combination
Hepatitis B virus
Hepatitis B, Chronic - drug therapy
Humans
Retrospective Studies
Tenofovir
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with chronic hepatitis B (CHB) who were administered tenofovir disoproxil fumarate (TDF)-based combination therapy after receiving multiple drugs are frequently switched to TDF monotherapy in South Korea. We evaluated the efficacy and safety of switching to TDF monotherapy from TDF-based combination therapy over 5 years. This was a retrospective study of multidrug-experienced CHB patients who switched from TDF-based combination therapy to TDF monotherapy after achieving a virologic response (VR;
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.00275-22